STERIS price to free cash flow STE

Market value divided by free cash flow over the last twelve months, since 2020.

Today, Oct 23, 2026: 24.5×
7-year median: 37.7×
Against its 7-year history: 8th; percentile: 0 is its lowest day, 100 its highest
7-year range: 20.3× to 60.8×
Peer median: 22.0×

STERIS' price to free cash flow is 24.5× as of Oct 23, 2026.

That is below its 7-year median of 37.7×, lower than on 92% of days in the last 7 years.

Over that time it ranged from 20.3× in Jun 2026 to 60.8× in Dec 2021.

The median for 10 healthcare stocks of a similar size is 22.0×.

Price to free cash flow over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	24.5×	20.3×	27.4×
2025	26.1×	25.5×	32.9×
2024	30.2×	30.1×	41.2×
2023	40.6×	36.8×	59.9×
2022	46.2×	34.5×	60.6×
2021	60.8×	31.4×	60.8×
2020	40.5×	28.9×	42.0×

Against its peers

Companies in Healthcare nearest STERIS' size, closest first, today.

Company	Price to free cash flow
STESTERIS	24.5×
INCYIncyte	12.2×
THCTenet Healthcare	7.2×
UTHRUnited Therapeutics	23.1×
LHLabcorp	23.1×
DGXQuest Diagnostics	19.8×
ZBHZimmer Biomet	12.3×
MEDPMedpace	26.4×
WSTWest Pharmaceutical Services	63.2×
RVTYRevvity	31.7×
DXCMDexCom	20.9×
Peer median	22.0×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on STERIS

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.